Table 1 Characteristics of 82 NPC patients with residual cervical lymphadenopathy

Total

68

14

Sex

0.045^¶

 Male

52 (76.5)

7 (50.0)

 Female

16 (23.5)

7 (50.0)

Pathological type

0.133^&

 WHO type II

2 (2.9)

2 (14.3)

 WHO type III

66 (97.1)

12 (85.7)

T stage^a

 T1

0 (0)

1 (7.1)

 T2

24 (35.3)

4 (28.6)

 T3

35 (51.5)

7 (50.0)

 T4

9 (13.2)

2 (14.3)

N stage^a

 N1

13 (19.1)

3 (21.4)

 N2

34 (50.0)

7 (50.0)

 N3

21 (30.9)

4 (28.6)

Clinical stage^a

0.179^¶

 II

7 (10.3)

4 (28.6)

 III

34 (50.0)

5 (35.7)

 IV

27 (39.7)

5 (35.7)

EBV DNA before treatment (copies/mL)

0.252^¶

 ≤ 4000

23 (33.8)

7 (50.0)

 > 4000

45 (66.2)

7 (50.0)

EBV DNA before surgery (copy/mL) < 0.001^#

 0

32 (47.1)

14 (100)

 > 0

36 (52.9)

0 (0.0)

VCA-IgA

0.988^¶

 < 1:320

29 (42.6)

6 (42.9)

 ≥ 1:320

39 (57.4)

8 (57.1)

EA-IgA

0.196^¶

 < 1:20

27 (39.7)

3 (21.4)

 ≥ 1:20

41 (60.3)

11 (78.6)

Size of lymph node 0.747^¶

 < 3 cm

42 (61.8)

8 (57.1)

 ≥ 3 cm

26 (38.2)

6 (42.9)

Lymph node invasion 1.000^#

 Yes

4 (5.9)

0 (0.0)

 No

64 (94.1)

14 (100)

Lymph node necrosis 0.865^¶

 Yes

16 (23.5)

3 (21.4)

 No

52 (76.5)

11 (78.6)

Treatment for cervical lymphadenopathy

0.285^#

 Surgery alone

54 (79.4)

14 (100)

 Surgery + chemotherapy

9 (13.2)

0 (0.0)

 Surgery + radiotherapy

5 (7.5)

0 (0.0)

Treatment for NPC

 Radiotherapy alone

4 (5.9)

1 (7.15)

 CCRT

22 (32.4)

 NAC + CCRT

38 (55.9)

7 (50.0)

 CCRT + AC

4 (5.9)

1 (7.15)

Irradiation technique

1.000^&

 2D-RT

7 (10.3)

1 (7.1)

 IMRT

61 (89.7)

13 (92.9)